Royal Government of Bhutan, Merck and Australian Cervical Cancer Foundation Partner on Vaccination Program with GARDASIL(R) for Girls and Young Women of Bhutan

Six-year program provides vaccine for country’s entire eligible population of 12 – 18 year old girls and young women

Merck & Co., Inc.

Categories:Corporate Social Responsibility, Health & Wellness

Posted: May 05, 2010 – 08:00 AM EST

THIMPHU, Bhutan, May. 05 /CSRwire/ – The Royal Government of Bhutan, Merck (which is known as MSD outside the United States and Canada) and the Australian Cervical Cancer Foundation (ACCF) today launched a national vaccination program with GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls and young women in Bhutan. In an effort to reduce the burden of cervical cancer, which affects more women in Bhutan than any other cancer, girls and young women between the ages of 12 and 18 will be offered vaccination with GARDASIL as part of this initiative.

The six-year program led by Her Majesty the Royal Grandmother Ashi Kesang Choeden Wangchuck and the Bhutan Ministry of Health will provide vaccination with GARDASIL starting today. Bhutan is the first low income country in the world to implement a national vaccination program with an HPV cancer vaccine.

“Vaccination programs such as the one we launched today play an important role in helping to protect the women of our country,” said Dr. Ugen Dophu, director, Department of Public Health, Ministry of Health, Bhutan. “It has long been a priority of ours to make health programs like this available to women of our country. We’re pleased to have the support of Merck and the ACCF on such an important initiative.”

Merck is providing GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], to the program partners at no cost in the first year and for the remaining five years will provide it at an access price at which Merck will not profit. In addition, Merck is providing additional support for implementation of the program. The Royal Government of Bhutan is committed to ensuring sustainability of this program beyond the six year partnership with Merck and ACCF.

“Cervical cancer represents a significant public health problem for Bhutan and the impact on affected women, their families and their communities is great. Merck is committed to helping improve access to GARDASIL in Bhutan and in other resource-limited countries around the world where the prevalence of cervical cancer is high,” said Dr. Mark Feinberg, vice president, Medical Affairs and Policy, Merck Vaccines. “Working in partnership with committed governments and other public and private sector partners is critical to the success of any program developed to enable women in low income countries to benefit from vaccination against cervical cancer.”


Note – the category postings “Corporate Responsibility,” Health and Wellness.”

HPV vaccines do not protect women from getting cervical cancer – they allegedly protect against two out of 99+ viruses that may cause cervical cancer.  Blatant lies. and fear mongering….this is corporate responsibility?


Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.